comparemela.com

Prnewswire Oxford Biotherapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Initial data from Phase 1 dose escalation part of the trial, assessing OBT076 in adult patients with advanced solid tumors, indicated that OBT076 was generally.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.